Halper Sadeh LLC Investigates Silence Therapeutics plc Acquisition
Investor rights law firm Halper Sadeh LLC is investigating whether the proposed acquisition of Silence Therapeutics plc by Merck KGaA provides fair value to shareholders.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Investor rights law firm Halper Sadeh LLC is investigating whether the proposed acquisition of Silence Therapeutics plc by Merck KGaA provides fair value to shareholders.
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.